Shots:

• The P-III SOLO3 study results involves assessing of Lynparza (300mg- bid) vs CT (paclitaxel/topotecan /pegylated liposomal doxorubicin/gemcitabine) in 266 patients in a ratio (2:1) with 2L+ platinum-sensitive relapsed BRCA1/2-mutated (gBRCAm) advanced ovarian cancer
• The P-III SOLO3 study results: improvement in ORR (72.2% vs 51.4%); PFS (13.4 mos. vs 9.2mos.); safe & tolerable- presented at ASCO 2019
• Lynparza is a PARP inhibitor- targeted for DNA damage response (DDR) pathway deficiencies- including BRCA mutations and has received approval in 64 & 38 countries as a maintenance treatment of platinum-sensitive relapsed ovarian cancer & 1L gBRCAm HER2- metastatic breast cancer respectively

Click here to­ read the full press release  

Ref: AstraZeneca | Image: AstraZeneca